{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:53:22Z","timestamp":1794020002751,"version":"4.8.0"},"reference-count":30,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2024,2,13]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a peripheral nerve disorder characterised by weakness and sensory loss. We assessed the neonatal Fc receptor inhibitor rozanolixizumab for CIDP management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>CIDP01 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03861481\">NCT03861481<\/jats:ext-link>) was a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a study. Adults with definite or probable CIDP receiving subcutaneous or intravenous immunoglobulin maintenance therapy were randomised 1:1 to 12 once-weekly subcutaneous infusions of rozanolixizumab 10\u2009mg\/kg or placebo, stratified according to previous immunoglobulin administration route. Investigators administering treatment and assessing efficacy, and patients, were blinded. The primary outcome was a change from baseline (CFB) to day 85 in inflammatory Rasch-built Overall Disability Scale (iRODS) score. Eligible patients who completed CIDP01 entered the open-label extension CIDP04 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04051944\">NCT04051944<\/jats:ext-link>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In CIDP01, between 26 March 2019 and 31 March 2021, 34 patients were randomised to rozanolixizumab or placebo (17 (50%) each). No significant difference in CFB to day 85 in iRODS centile score was observed between rozanolixizumab (least squares mean 2.0 (SE 3.2)) and placebo (3.4 (2.6); difference \u20131.5 (90% CI \u20137.5 to 4.5)). Overall, 14 (82%) patients receiving rozanolixizumab and 13 (76%) receiving placebo experienced a treatment-emergent adverse event during the treatment period. Across CIDP01 and CIDP04, rozanolixizumab was well tolerated over up to 614 days; no clinically meaningful efficacy results were seen. No deaths occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Rozanolixizumab did not show efficacy in patients with CIDP in this study, although this could be due to a relatively high placebo stability rate. Rozanolixizumab was well tolerated over medium-to-long-term weekly use, with an acceptable safety profile.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2023-333112","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T17:20:23Z","timestamp":1715361623000},"page":"845-854","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study"],"prefix":"10.1136","volume":"95","clinical-trial-number":[{"clinical-trial-number":"nct03861481","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04051944","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03861481","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04051944","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-8264","authenticated-orcid":false,"given":"Luis","family":"Querol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"De S\u00e8ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Dysgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T Hemanth","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rivner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kiessling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Marmol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bozorg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anny-Odile","family":"Colson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Massow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Eftimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"2025021202450621000_95.9.845.1","doi-asserted-by":"publisher","DOI":"10.1159\/000494291"},{"key":"2025021202450621000_95.9.845.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30144-9"},{"key":"2025021202450621000_95.9.845.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2011.121"},{"key":"2025021202450621000_95.9.845.4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000331011","article-title":"Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment","volume":"66","author":"Galldiks","year":"2011","journal-title":"Eur Neurol"},{"key":"2025021202450621000_95.9.845.5","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072025","article-title":"Immunoadsorption and plasma exchange in seropositive and seronegative immune-mediated neuropathies","volume":"9","author":"Davies","year":"2020","journal-title":"J Clin Med"},{"key":"2025021202450621000_95.9.845.6","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309042"},{"key":"2025021202450621000_95.9.845.7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40120-020-00190-8","article-title":"Pathophysiology of chronic inflammatory demyelinating polyneuropathy: insights into classification and therapeutic strategy","volume":"9","author":"Koike","year":"2020","journal-title":"Neurol Ther"},{"key":"2025021202450621000_95.9.845.8","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000387","article-title":"Serum IgG subclasses in autoimmune diseases","volume":"94","author":"Zhang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2025021202450621000_95.9.845.9","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"2025021202450621000_95.9.845.10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrneurol.2017.84","article-title":"Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications","volume":"13","author":"Querol","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"2025021202450621000_95.9.845.11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jns.12455","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision","volume":"26","author":"Van den Bergh","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"2025021202450621000_95.9.845.12","article-title":"Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"11","author":"Hughes","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025021202450621000_95.9.845.13","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"key":"2025021202450621000_95.9.845.14","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1505464"},{"key":"2025021202450621000_95.9.845.15","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1007\/s00415-018-9082-6","article-title":"Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients","volume":"265","author":"Dorst","year":"2018","journal-title":"J Neurol"},{"key":"2025021202450621000_95.9.845.16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/jns.12262","article-title":"Individualized immunoglobulin therapy in chronic immune\u2010mediated peripheral neuropathies","volume":"23","author":"Allen","year":"2018","journal-title":"J Peripher Nerv Syst"},{"key":"2025021202450621000_95.9.845.17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor Rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025021202450621000_95.9.845.18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/mus.26898","article-title":"Daily grip strength response to intravenous immunoglobulin in chronic immune neuropathies","volume":"62","author":"Doneddu","year":"2020","journal-title":"Muscle Nerve"},{"key":"2025021202450621000_95.9.845.19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/jns.12497","article-title":"Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: a post-hoc analysis of the immunoglobulin overtreatment in CIDP trial","volume":"27","author":"van Veen","year":"2022","journal-title":"J Peripher Nerv Syst"},{"key":"2025021202450621000_95.9.845.20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"2025021202450621000_95.9.845.21","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.12688\/f1000research.8206.1","article-title":"Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms","volume":"5","author":"Phillips","year":"2016","journal-title":"F1000Res"},{"key":"2025021202450621000_95.9.845.22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/jns.12470","article-title":"An approach to assessing immunoglobulin dependence in chronic inflammatory demyelinating inflammatory polyneuropathy","volume":"26","author":"Kapoor","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"2025021202450621000_95.9.845.23","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/brain\/awac054","article-title":"Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"145","author":"Adrichem","year":"2022","journal-title":"Brain"},{"key":"2025021202450621000_95.9.845.24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40364-019-0154-2","article-title":"Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy","volume":"7","author":"Khoo","year":"2019","journal-title":"Biomark Res"},{"key":"2025021202450621000_95.9.845.25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(18)30202-3","article-title":"Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP trial): a double-blind, multicentre, randomised controlled trial","volume":"17","author":"Hughes","year":"2018","journal-title":"Lancet Neurol"},{"key":"2025021202450621000_95.9.845.26","unstructured":"GlobeNewsWire . Argenx reports positive topline data from ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy [GlobeNewsWire]. 2023. Available: https:\/\/www.globenewswire.com\/news-release\/2023\/07\/17\/2705309\/0\/en\/argenx-Reports-Positive-Topline-Data-from-ADHERE-Study-of-VYVGART-Hytrulo-in-Patients-with-Chronic-Inflammatory-Demyelinating-Polyneuropathy.html [Accessed 25 Oct 2023]."},{"key":"2025021202450621000_95.9.845.27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/jns.12402","article-title":"Placebo effect in chronic inflammatory demyelinating polyneuropathy: the PATH study and a systematic review","volume":"25","author":"Lewis","year":"2020","journal-title":"J Peripher Nerv Syst"},{"key":"2025021202450621000_95.9.845.28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"van Schaik","year":"2018","journal-title":"Lancet Neurol"},{"key":"2025021202450621000_95.9.845.29","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and safety of Rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"key":"2025021202450621000_95.9.845.30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002003"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2023-333112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T10:46:24Z","timestamp":1739357184000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2023-333112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,8,16]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/jnnp-2023-333112"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2023-333112","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}